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Abstract
Background: Epstein-Barr virus (EBV) establishes lifelong infections in its human host. The virus is associated with a
broad range of malignancies of lymphoid and epithelial origin, including Burkitt’s lymphoma, post-transplant
lymphoproliferative disease, nasopharyngeal carcinoma and gastric carcinoma. During the latent phase of its life
cycle, EBV expresses more than 40 mature miRNAs that are highly abundant in tumor cells and may contribute to
oncogenesis. Although multiple studies have assessed the relative expression profiles of EBV miRNAs in tumor cells,
data linking these expression levels to functional target knockdown are mostly lacking. Therefore we set out to
systematically assess the EBV miRNA expression levels in EBV+ tumor cell lines, and correlate this to their functional
silencing capacity in these cells.
Results: We provide comprehensive EBV miRNA expression profiles of the EBV+ cell lines C666-1 (nasopharyngeal
carcinoma), SNU-719 (gastric carcinoma), Jijoye (Burkitt’s lymphoma), and AKBM (Burkitt’s lymphoma) and of EBV− cells
ectopically expressing the BART miRNA cluster. By deep sequencing the small RNA population and conducting
miRNA-reporter experiments to assay miRNA potency, we were able to compare the expression profiles of the
EBV miRNAs with their functional silencing efficacy. We observe a strong correlation between miRNA expression
levels and functional miRNA activity. There is large variation in expression levels between EBV miRNAs in a given
cell line, whereas the relative expression profiles are well maintained between cell lines. Furthermore, we show
that miRNA arm selection bias is less pronounced for gamma-herpesvirus miRNAs than for human miRNAs.
Conclusion: We provide an in depth assessment of the expression levels and silencing activity of all EBV miRNAs in
B- and epithelial cell lines of different latency stages. Our data show a good correlation between relative EBV miRNA
expression levels and silencing capacity, and suggest preferential processing of particular EBV miRNAs irrespective of
cell-type. In addition to encoding the largest number of precursor miRNAs of all human herpesviruses, EBV expresses
many miRNAs precursors that yield two functional miRNA strands, rather than one guide strand and a non-functional
passenger strand. This reduced strand bias may increase the size of the EBV miRNA targetome.
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Background
MicroRNAs (miRNAs) are small RNA molecules of ~22
nucleotides in length that regulate gene expression by
binding to target mRNAs in RNA-induced silencing
complexes (RISC). Mechanisms for miRNA-mediated
target gene downregulation include enhanced mRNA
degradation, suppression of translation and in rare cases
slicing of the mRNA at the target site (reviewed in [1]).
In the last decade, many virus-encoded miRNAs have
been identified, predominantly within the genomes of
large dsDNA viruses such as herpesviruses. The two
members of the gamma-herpesvirus subfamily that infect
humans, Kaposi Sarcoma Associated Herpesvirus
(KSHV, HHV-8) and Epstein-Barr virus (EBV, HHV-4),
express large clusters of miRNAs during their latent
phase (reviewed in [2]). Since very few viral proteins are
expressed during latency, the expression of these miR-
NAs greatly expands the number of gene products
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available to manipulate the host cell. Indeed, EBV miR-
NAs play important roles in regulating EBV-induced B
cell transformation [3–5] and downmodulate pro-apoptotic
proteins such as PUMA [6], Bim [7], Bid [8], caspase 3 [5]
and others [9]. Additionally, the EBV miRNAs contribute
to immune evasion by targeting the NK cell ligand MICB
[10], the chemokine CXCL11 [11] and the inflammasome
component NLRP3 [12].
EBV establishes a lifelong infection in over 90 % of the
adult human population, where it predominantly resides
in a latent stage in the memory B cell compartment.
During its life cycle, the virus passes through different
phases that are characterized by distinct gene expression
patterns [13]. After primary B cell infection, EBV gradually
shuts down its protein expression. Initially, during the
latency III stage, all EBNA (EBV nuclear antigens) and
LMP (latent membrane protein) proteins are expressed.
This is followed by the latency II stage where only EBNA1
and LMP proteins are expressed. During the subsequent
latency I stage, protein expression is restricted to EBNA-1
alone. Through occasional reactivation and possibly lytic
replication in epithelial cells of the oropharynx, EBV can
spread to new hosts [14]. Although primary EBV infection
usually proceeds asymptomatically, it is the causative
agent for infectious mononucleosis. Furthermore, EBV
infection is associated with a number of malignancies of
epithelial, B cell and (occasionally) NK/T cell origin [13].
EBV-associated tumors display one of the three gene
expression profiles described above. Burkitt’s lymphoma
(BL) for instance, is characterized by a latency I program,
although EBV frequently switches to latency III in vitro
[15]. Hodgkin’s lymphoma (HL) and nasopharyngeal car-
cinoma (NPC) follow the latency II program, whereas
gastric carcinoma (GC) is characterized by a latency I ex-
pression pattern, although occasionally LMP2A can be
detected as well [16–18]. In EBV-associated lymphomas of
immunosuppressed individuals, EBV expresses the largest
set of latent genes (latency III) [19]. Also B lymphocytes
transformed with EBV in vitro (lymphoblastoid cell lines,
LCLs) display the latency III gene expression pattern [20].
Intriguingly, whereas viral protein expression is strictly
regulated during the EBV latency stages, viral miRNAs
are expressed throughout all stages of latency. EBV miR-
NAs are expressed in clusters and are named BART and
BHRF1 miRNAs [21–23]. The BART miRNAs are located
in introns of the latent BART transcripts (BARTs) that are
expressed during all latency phases. Upon induction of the
lytic cycle, the expression of the BARTs is increased,
which coincides with a modest increase in mature BART
miRNA expression levels [24]. The BHRF1 miRNAs lie
upstream (miR-BHRF1-1) or downstream (miR-BHRF1-2,
miR-BHRF1-3) the protein-coding BHRF1 gene and are
mainly processed from latent EBNA transcripts that are
highly expressed in latency III B cells. EBV reactivation
results in expression of lytic BHRF1 mRNA from
which miR-BHRF1-2 and miR-BHRF1-3 can be proc-
essed [24, 25]. The relative abundance of EBV miR-
NAs has been assessed in several human tissues and
cell lines via deep sequencing, microarray, or qPCR
techniques [8, 9, 24, 26–32]. Although insightful, these
evaluations are limited to the relative expression profiles
of EBV miRNAs without correlating this to their bio-
logical silencing potential. EBV miRNA targets have been
identified by various approaches, including PAR-CLIP
studies [9, 32], but a comprehensive analysis of the activ-
ities of all EBV miRNAs is lacking. Here, we set out to
connect these two parameters experimentally. For this, we
monitored miRNA activity of both strands from each
EBV-encoded pre-miRNA in four different cell lines that
cover the main latency stages of EBV. In parallel we per-
formed small RNA deep sequencing in these same lines
and correlated their relative expression level to functional
target knockdown. Our data show a strong correlation
between miRNA expression level and functional target
knockdown. EBV miRNA expression profiles are highly
consistent between cell lines, where miRNAs abundantly
expressed in one cell line are also abundantly expressed
in other EBV+ cell lines. Expression of the BART cluster
in EBV-negative cells maintains the same hierarchy. In-
triguingly, we noticed that there is considerably less
strand bias in the expression of viral miRNAs as com-
pared to human miRNAs: viral miRNAs have a higher
incidence of expressing both miRNA strands in cells,
thereby potentially enhancing the regulatory capacity of
these miRNA genes.
Results and discussion
Functional expression profiling using miRNA reporters
In order to study the functional expression of EBV miR-
NAs in infected cells, lentiviral reporter constructs con-
taining a single perfect miRNA binding site downstream
of the fluorescent mCherry gene (Fig. 1a) were designed
for all mature EBV miRNAs based on their sequences
annotated in miRBase [33]. Although many miRNA hair-
pins are known to favor selection of one arm of the
duplex over the other (the guide strand versus the star
strand), both arms of a miRNA may be functional and
capable of downregulating target mRNAs. We aimed at
generating a comprehensive profile of the functional
expression of all mature EBV miRNAs including the
ones lacking miRBase annotation. To assess the func-
tional expression of the latter ones, we designed miRNA
reporters based on previous deep sequencing studies
[34] or we introduced the complementary sequence of
the entire miRNA arm including several adjacent nucle-
otides as a potential target site in our lentiviral mCherry
reporter constructs. A complete list of the EBV miRNA
sensor sequences is presented in Additional file 1.































































































































































































































































































































































































































































































































































































































































































































































































Fig. 1 (See legend on next page.)
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We selected four EBV+ cell lines for functional screen-
ing: SNU-719 (type 1 EBV, gastric carcinoma, latency I/II,
[35]), C666-1 (type 1 EBV, nasopharyngeal carcinoma,
latency II), Jijoye (type 2 EBV, Burkitt’s lymphoma, latency
III) and AKBM (type 1 EBV, Burkitt’s lymphoma, latency
I, Akata strain). Additionally, in order to study EBV
miRNA expression outside the context of virus infection,
we analyzed EBV-negative HK1 (nasopharyngeal epithelial
cell line) ectopically expressing the complete BART
miRNA cluster but lacking BART2 (“HK1-miR-BART”).
We next measured the functional downregulation of each
miRNA reporter in these five cell lines (Fig. 1b–f ). As ex-
pected, we observed differential downregulation of the
miRNA reporter constructs, and these assessments were
highly reproducible between experiments (Additional
file 2). The majority of the BART miRNAs induced
potent downregulation of reporters in the carcinoma cell
lines (Fig. 1b–c). These findings are consistent with high
expression levels of BART miRNAs in epithelial cells re-
ported previously [8, 30, 36]. BART miRNA-mediated
sensor downregulation in HK1-miR-BART cells was simi-
lar to that in EBV+ epithelial cells (Fig. 1f). For all miR-
NAs, at least one of the two strands induced potent target
knockdown (>70 % repressed in the carcinoma cell lines),
with the exception of miR-BART21 and miR-BART20 for
which both strands induced only minor target downregu-
lation (±50 %). In agreement with our data, large varia-
tions in expression levels between BART miRNAs have
been observed previously [21, 29, 37, 38]; the mechanism
behind this regulation remains to be determined.
The BHRF1 miRNAs are processed from EBNA-encoding
transcripts initiated at the Cp or Wp promoter [21, 24],
which are active during latency III. In addition, miR-
BHRF1-2 and 3 can be processed from the 3’UTR of
the BHRF1 mRNA, a lytic transcript that has also been
detected in latent cells with an active Wp promoter
[39]. Consistent with this, we barely see functional expres-
sion of BHRF1 miRNAs in carcinoma cell lines C666-1
and SNU-719, in which the Qp promoter drives expres-
sion of EBNA1 and the Cp and Wp promoter are not
active (Fig. 1b–c). In contrast, in the latency III Jijoye
cells, miR-BHRF1-2-5p, miR-BHRF1-2-3p and miR-
BHRF1-3-5p potently downregulated their respective
reporters (Fig. 1d). The miR-BHRF1-1-3p and miR-BHRF1-
1-5p miRNAs do not show silencing activity in Jijoye cells.
This is likely the result of a single nucleotide change in the
3p arm of the miR-BHRF1-1 pre-miRNA [40], which may
preclude proper miR-BHRF1-1 expression.
The reporters for most of the miRNA strands absent
from miRBase (miR-BART12-5p, miR-BART15-5p, miR-
BART22-5p, miR-BHRF1-1-3p and miR-BHRF1-3-3p)
were not or barely downregulated in the various cell
lines tested, indicating that the registration of functional
mature EBV miRNAs in this database is quite complete.
However, although the miR-BART16-3p reporter was
clearly downregulated in most cell lines, this miRNA is
not annotated in miRBase and has not been analyzed in
any of the previously published qPCR profiling studies
of EBV+ samples.
A strong correlation in BART miRNA reporter down-
regulation was observed between SNU-719, C666-1 and
Jijoye (Fig. 2), i.e. in all three cell lines the same hierarchy
of miRNA potency was observed between individual
mature miRNAs. Remarkably, this relative expression pro-
file was also maintained in the EBV-negative HK1 cell line
expressing the BART miRNAs. This indicates that the
main determinants for BART pre-miRNA processing,
miRNA stability, RISC incorporation and target binding
lie in the primary miRNA sequence (pri-miRNA) and are
not affected significantly by viral sequences outside of the
miRNA cluster or by cell-type specific expression of host
cell genes. These findings are consistent with a study by
Qiu et al., [31] in which EBV miRNA expression patterns
were highly similar in tumor biopsies from various origins.
Although we observed comparable miRNA expression
patterns between cell lines, overall the BART miRNA re-
porters were less potently downregulated in the Jijoye cells
as compared to the epithelial cell lines. This observation
corresponds with a study by Cai et al. [21], where BART
transcript levels were reduced in Jijoye cells as compared
to C666-1 cells.
AKBM cells displayed a much-reduced potency of EBV
miRNA activity as compared to the other cell lines; the
majority of mature miRNAs induced only minor sensor
downregulation (ranging from 0 to 25 %), whereas only
miR-BART2-3p and miR-BART3-5p reduced mCherry ex-
pression by ±50 % (Fig. 1e, Additional file 3). Since these
reporters acted distinctively as compared to the majority
of EBV miRNA sensors, we tested whether they could be
targeted by human instead of viral miRNAs. Although
miR-BART2-3p and miR-BART3-5p reporters were not
downregulated in EBV-negative HK1 cells (data not
shown), we did observe a marked downregulation of
the BART3-5p sensor in EBV-negative subclones of the
Akata line which have lost the EBV genome (Additional
file 4). This suggests that the observed regulation of this
(See figure on previous page.)
Fig. 1 Functional EBV miRNA profiling using reporters. a Schematic representation of the lentiviral miRNA reporter construct used in this study
b–e Relative miRNA reporter expression in b C666-1, c SNU-719, d Jijoye, e AKBM, and f HK1-miR-BART. Reporter expression was normalized to
the empty control vector. miRNA binding decreases reporter expression; hence lower bars indicate higher functional miRNA expression. The
displayed values are averages of two independent experiments performed in triplicate (+SD). The bars are shown in genomic order
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reporter in EBV-positive AKBM cells is likely caused by
human miRNAs expressed in these cells, and not by viral
miRNAs. The miR-BART2-3p reporter, however, was not
downregulated in EBV-negative Akata cells, indicating
that this miRNA may be functional in AKBM cells. It is
unclear why miR-BART2-3p is more potent in AKBM
cells as compared to other EBV miRNAs expressed in
these cells.
Expression profiling using deep sequencing
To allow correlation of our functional EBV miRNA profil-
ing to mature miRNA expression levels, we next assessed
the relative abundance of all EBV miRNAs by deep se-
quencing. This yielded 32–41 million sequencing reads
per sample, after filtering of adapter sequences and low-
quality reads (Table 1, Additional file 5). Reads were
aligned to the human and EBV genome. The average read
length was ~22 nucleotides, of which the majority mapped
to miRNA sequences (75–97 %). The proportion of EBV
reads ranged from 23.5 % in Jijoye to only 1.4 % in AKBM
(Fig. 3a), suggesting that the poor miRNA reporter down-
regulation in the Akata-derived AKBM cells reflects low
expression levels of the given miRNAs. To ensure that the
relatively low expression of EBV miRNAs was not caused
by loss of EBV from a large percentage of cells, we con-
structed a reporter vector in which 5 EBV miRNAs target
sites were cloned downstream the mCherry reporter gene.
Upon introduction of this ‘super-sensor’ in AKBM cells,
we observed silencing in the majority of the cells which
was not seen in EBV-negative subclones of the Akata cell
line 2A8 and AK31 (Additional file 6), showing that
relatively low EBV miRNA expression was not caused by
absence of EBV from the AKBM cells.
For the C666-1, SNU-719, and Jijoye cells, there was a
clear inverse correlation between relative read counts (reads










































































































Fig. 2 Comparison of functional miRNA expression between different cell lines. miRNA reporter expression shown in Fig. 1 was compared
between the four EBV+ cell lines and the EBV− cell line HK1-miR-BART (expressing the whole BART cluster except BART2). Every dot represents the
relative reporter expression of a specific miRNA normalized to the control reporter. Since the BHRF1 miRNAs and BART2-3p and 5p were not in-
cluded in the lentiviral vector introduced in the HK1 cell line, these miRNAs were not expressed in this cell line and are therefore not depicted in
the HK1 plots. In AKBM the miRNA reporters were barely downregulated, making a comparison with the other cell lines less informative. These
plots are shown in Additional file 3. The dashed line indicates the diagonal (no difference in relative reporter expression between both cell lines)
Hooykaas et al. BMC Genomics  (2016) 17:644 Page 5 of 13
(Fig. 3b). However, the correlation between these readouts
within a single cell line (Fig. 3b) was less pronounced than
the correlation of either read counts (Additional file 7) or
reporter downregulation between two cell lines, e.g. the
C666-1 and SNU-719 cells (Fig. 2). This difference may
be explained by preferential deep sequencing of certain
miRNA sequences; studies have indicated that miRNA
sequencing bias can be introduced in the adapter ligation
procedure, thereby favoring certain mature miRNA se-
quences over others [41]. Moreover, it is unlikely that the
Table 1 Summary of next generation sequencing results
No. of reads No. of miRNA reads
cell line total genome mapped human EBV % EBV reads
SNU-719 38,071,531 36,469,805 (95.8 %) 30,596,909 4,770,947 13.5 %
C666-1 38,248,224 36,080,697 (94.3 %) 28,912,402 4,972,225 14.7 %
Jijoye 40,677,253 34,107,346 (83.8 %) 20,372,508 6,260,036 23.5 %
AKBM 38,448,698 32,740,447 (85.2 %) 24,085,169 338,613 1.4 %
HK1-miR-BART 38,817,502 36,773,337 (94.7 %) 33,230,276 2,046,878 5.8 %






















































































Fig. 3 Correlation between EBV miRNA deep sequencing read counts and miRNA reporter expression. a Pie charts indicating the proportion of
EBV and human derived miRNA sequences that mapped to miRNA loci for each indicated cell line. b Comparison of sequencing read counts
(read count per million reads) to relative miRNA reporter expression (normalized to control reporter) in C666-1, SNU-719, Jijoye and AKBM. Each
dot represents a single EBV miRNA. The dashed lines are linear regression curves of log-transformed read counts and reporter expression values
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potency of individual miRNAs depends solely on the rela-
tive abundance of this miRNA. Indeed, the relative location
of the miRNA target site in the 3’UTR impacts the potency
of regulation [42]. In our experiments however, the distance
between the mCherry reporter stop codon and the single
miRNA target site is identical for all reporters. Besides
target-site location, also seed-pairing stability (strength of
the interaction) and target site abundance have been shown
to influence miRNA activity [43].
We observed less miRNA reporter downregulation in
Jijoye cells as compared to epithelial cell lines, although
sequence read counts for given miRNAs were compar-
able (Figs. 1, and 3b, and Additional file 5). However,
since we only assessed the relative EBV miRNA abun-
dance (reads per million), it is possible that the Jijoye
cells may actually have low absolute levels of EBV miR-
NAs. Indeed, previous studies report lower absolute
BART miRNA expression levels in Jijoye as compared to
C666-1 [21, 37]. Similarly, we observed roughly 2–3 fold
lower relative EBV miRNA reads in the HK1-miR-BART
cells as compared to the C666-1 and SNU-719 cells
(Fig. 3a), although the potency of downregulation of the
miRNA sensors was comparable between these three
lines (Fig. 1). It is possible that the absolute EBV miRNA
levels is similar between these lines.
IsomiRs
Deep sequencing studies revealed that miRNAs can dis-
play extensive length and sequence variation [44]. These
variants, termed isomiRs, are generated by differential
Drosha/Dicer processing, trimming by exonucleases,
non-templated nucleotide additions, and RNA editing
events [45]. Indeed, we observed a large variety of
isomiRs for all EBV miRNAs in each of the EBV+ cell
lines analyzed. For many miRNAs less than 50 % of the
sequenced reads had the exact canonical sequence as re-
ported in miRBase (Additional file 5). Additionally, the
most abundant sequence for several EBV miRNAs did
not match the annotated sequence deposited in miR-
Base. The majority of isomiRs displayed 3’end variation,
which is not expected to severely impact miRNA activity
due to preservation of the 5’ end seed sequence. Never-
theless, the most abundant miR-BART10-3p sequence
lacks a single 5’ nucleotide as compared to the canonical
sequence in the EBV+ cell lines. Besides for miR-
BART10-3p, high frequencies of isomiRs with alternative
5’ ends were also apparent for miR-BART2-3p, miR-
BART16-3p and miR-BART5-5p (Additional file 5). Of
these, only miR-BART10-3p and miR-BART5-5p repre-
sent the dominant arm of the miRNA duplex. For miR-
BART5-5p, 38–60 % of the reads have a single nucleo-
tide deletion at their 5’ end as compared to miRBase
(Additional file 5). It is likely that these 5’ end variants
will have an altered gene target repertoire as compared
to the canonical miRNA sequences. Detection of the 5’
end variability prompted us to assess whether our
miRNA reporters could be targeted by these isomiRs.
Fortunately, only a minority of the reads had an elon-
gated 5’ end that could obstruct activity towards our re-
porter construct. The relatively abundant 5’ variants of
miR-BART10-3p, miR-BART2-3p, and miR-BART5-5p
were truncated at their 5’ termini, rendering the re-
porters used in these studies still functional. For miR-
BART16-3p, however, ~40 % of the sequences possessed
a 2 nt extension at the 5’ end for which no complemen-
tary bases were present in our miRNA reporter con-
struct. It is therefore possible that we underestimate the
functional activity of this specific miRNA.
Non-templated nucleotides can be added to precursor
or mature miRNA 3’ termini by terminal nucleotidyl
transferases (TNTs). The functional implications of these
modifications are not fully understood, although miRNA
uridylation and adenylation have been reported to im-
pact miRNA stability [46–49] and potency [50, 51], and
may act as a molecular signal to facilitate miRNA trans-
port within and between cells [52]. We observed low
levels of non-templated nucleotide additions (NTAs) to
EBV miRNAs in our cell lines (ranging from 0 to 24 %)
where adenine and uracil additions were most frequent.
Intriguingly, we observed a clear correlation between the
frequency of NTAs for given miRNAs between cell lines
(Fig. 4a and b), where some EBV miRNAs were clearly
preferentially adenylated or uridylated. In line with our
findings, previous reports describe sequence specificity
of terminal nucleotidyl transferases [48, 51, 53]. Whether
these NTAs are important for EBV miRNA function re-
mains to be determined.
Reduced strand bias of gamma-herpesvirus miRNAs
Upon loading of a miRNA duplex onto Argonaute, one
miRNA strand/arm (the guide RNA) is selected whereas
the other one (passenger strand) is degraded [54]. For
many miRNAs, there is a strong bias towards selection
of one strand over the other, which results in profound
differences in abundance of both miRNA strands within
cells [55]. Although we saw a clear strand bias for hu-
man miRNAs, this phenomenon appeared much weaker
for EBV miRNAs. For approximately half of the BART
miRNAs, one of both arms was clearly dominant,
whereas in a third of cases both strands potently down-
regulated their reporter (Fig. 1). This same feature was
apparent in the deep-sequencing data: where for human
miRNAs the median ratio between the most and least
abundant miRNA strand was 1:186, for EBV miRNAs
this was only 1:11 (Fig. 5a, left two bars). For a quarter
of the EBV miRNAs there was a less than twofold differ-
ence between both strands, which applied to only 8 % of
the human miRNAs. This difference in miRNA arm bias
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between human and EBV miRNAs was apparent for
both high and low expressed miRNAs, as subdividing
the miRNAs based on abundance yielded the same trend
(Fig. 5a, right six bars). This phenomenon was not
limited to C666-1 cells as we observed the same in
SNU-719, Jijoye, and AKBM cells in our dataset and for
Akata-LCL and BC-1 cells in sequencing data from
other research groups (Fig. 5b).
We next extended our strand-bias analysis to non-EBV
gamma-herpesvirus miRNAs (Fig. 5c). Intriguingly, also
KSHV miRNAs expressed in BC-1 cells displayed reduced
strand bias as compared to host miRNAs and the same
was apparent for rhesus lymphocryptovirus (rhLCV, an
EBV ortholog) miRNAs in rhesus monkey LCLs (Fig. 5b).
Hence, it appears that gamma-herpesvirus miRNAs have
retained or acquired the ability of both strands to func-
tionally downregulate target genes.
The main feature determining arm selection is the
thermodynamic stability of the miRNA duplex, whereby
the miRNA arm with the least stable 5’ end is typically
the guide strand that is loaded into RISC [56–58]. Also
the secondary structure of the miRNA [59] and the
identity of its first nucleotide [58, 60, 61] have been de-
scribed to impact strand selection. How this reduced
strand bias for gamma-herpesvirus miRNAs is obtained
or retained and why this occurs remains to be determined.
In principle, reducing strand bias may allow EBV to
expand the number of target genes it regulates. Increasing
the expression of miRNAs from one to two strands can be
viewed as a genomic space-saving approach to enlarge
regulatory capacity. This may be especially favorable for
viruses since they are more constrained in their genome
size than their host.
Conclusions
We have provided comprehensive functional and relative
expression profiles for all EBV miRNAs in four EBV+ cell
lines representing different latency stages. In general, there
is good concordance between the relative expression levels
of miRNAs and their potential to silence target genes. The
dominance of particular miRNAs over others is shared by
all four cell lines and an EBV− cell line in which the BART
miRNAs were introduced through lentiviral transduction.
This observation argues against an important role for cell-
specific or virus-specific factors in regulating miRNA activ-
ity or abundance (apart from promoter usage), but rather
suggests that the (pri-) miRNA sequence determines func-
tional expression levels. Our deep sequencing datasets
provide in depth information on EBV miRNA sequence














Non-templated 3’ uridine additions




























































































Fig. 4 Frequencies of non-templated nucleotide additions to miRNAs correlate between cell lines. Comparison between the fractions of miRNA
reads harboring non-templated adenine a or uridine b additions at their 3’ terminus in pairs of cell lines. Each dot represents a mature EBV
miRNA. Presented are Spearman correlation coefficient rs and p-value of correlations (two-tailed, Gaussian approximation)
Hooykaas et al. BMC Genomics  (2016) 17:644 Page 8 of 13
specificity by 5’end heterogeneity. Interestingly, EBV not
only expresses the highest numbers of miRNAs of all
human viruses; it also has increased regulatory capacity by




For the cloning of miRNA reporters, single perfect miRNA
binding sites were introduced 29 bp downstream the
mCherry reporter gene in the pSicoR-EF1a-PuroR-T2A-



















































































Fig. 5 Gamma-herpesvirus miRNAs display less strand bias than host miRNAs. Box and whisker plots showing the miRNA arm ratios (deep sequencing
read counts of the most abundant strand divided by the least abundant strand) in different cell lines. We limited the analysis to miRNAs with at least
1000 reads for the sum of both strands. The Tukey method was used for plotting the boxes, whiskers and outliers. miRNAs with one arm not detected
are represented by a dot at the top of the graph (∞). a Arm ratios for human and EBV miRNAs in C666-1 cells. For the right six bars the miRNAs were
divided in three different bins according to the read count number of the most abundant strand. b Arm ratios for human and EBV miRNAs in the
EBV+ cell lines used in this study and EBV+ Akata-LCL and BC-1 cells (coinfected with EBV+ and KSHV+) deep sequenced in previous studies.
c Arm ratios for KSHV/rhLCV and host miRNAs in BC-1 cells coinfected with EBV+ and KSHV+ and rhLCV infected rhesus macaque LCLs
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mCherry vector (described elsewhere, manuscript in prep-
aration). See Additional file 1 for sequences cloned. Of
note: the deep-sequencing analysis identified a single
nucleotide change (position 17, T changed to C) in the
mature miR-BART19-5p miRNA sequence in the C666-
1 strain. Therefore, the miR-BART19-5p miRNA sensor
used in the C666-1 cells to monitor miRNA activity
does not fully match the miR-BART19-5p sequence
expressed in these cells.
We ectopically expressed EBV miRNAs in EBV− HK1
cells from the pLenti-Blast-eGFPintron vector (de-
scribed elsewhere, manuscript in preparation). The
miRNAs were cloned into an intron located in an eGFP
marker gene driven by the EF1a promoter. Briefly, the
EBV BART region was PCR amplified from genomic
EBV DNA in three different PCR reactions (BART3 to
6, 21 to 18 and 7 to 14), which were subsequently com-
bined into the pLenti-Blast-eGFPintron vector. All con-
structs were verified by Sanger sequencing.
Cells and lentiviral transduction
Jijoye and 293 T human embryonic kidney cells were
obtained from the ATCC (American Type Culture
Collection). HK1 cells [62] were kindly provided by
Prof. Dr. G. Tsao (The University of Hong Kong, Hong
Kong). SNU-719 cells (originally derived from the
Korean Cell Line Bank) and C666-1 were a kind gift
from Prof. Dr. J. Middeldorp (VU University Medical
Center, Amsterdam). As C666-1 cells can lose LMP1
and LMP2A expression in culture, the LMP1/2A ex-
pression status was verified by TaqMan qPCR which
showed expression of both viral transcripts in our cells
(data not shown). The EBV+ AKBM cell line [63] and
EBV− AK31 and 2A8 cell lines are derived from the
Japanese Burkitt’s lymphoma cell line Akata. Cell lines
were maintained in RPMI (Roswell Park Memorial Insti-
tute) 1640 supplemented with heat-inactivated 10 % fetal
calf serum, 2 mM glutamine and antibiotics. Tissue
culture flasks for culturing C666-1 cells were coated
with fibronectin (Sigma F1141, [64]). Lentiviruses were
produced via standard lentiviral production protocols
using third-generation packaging vectors. Transductions
of EBV+ cell lines were performed by spin infections at
1000 g for 1.5 h at 33 °C in the presence of 4 ug/ml poly-
brene and lentivirus. To obtain a pure population of
BART miRNA expressing HK1 cells, lentivirally trans-
duced cells were FACS sorted on a BD FACS Aria II based
on eGFP expression.
MiRNA reporter assay
Cells were lentivirally transduced at low MOI to
achieve single lentiviral integrations, allowed to re-
cover for ± 1 week, fixed, and analyzed by flow cy-
tometry on a BD Canto II flow cytometer. FlowJo
software (Treestar) was used for analyzing the flow
cytometric data. The gating strategy consisted of select-
ing live cells (based on forward and side scatter) and then
gating on mCherry-positive cells (thereby gating out
untransduced cells). To calculate relative reporter expres-
sion, the mCherry geometric means of cells harbouring
the miRNA reporters were normalized against those of
cells harbouring the empty control vector.
Construction of small RNA libraries and deep sequencing
RNA was isolated using Trizol according to manu-
facturer’s instructions (Life Technologies). Integrity
of the RNA was verified using the Agilent 2100
Bioanalyzer (RIN scores were 10.0). Sequencing of
small RNA was performed by BGI (Hong Kong,
China), briefly: 3’ and 5’ adapters were ligated to
size-selected RNA molecules (~18–30 nt length),
followed by reverse transcription using SuperScript
II (Invitrogen). cDNA was PCR amplified, after which
clusters were generated using an Illumina cBot cluster
amplification system. Single-end sequencing by synthesis
was performed on the HiSeq 2000 platform using
the TruSeq SBS Kit-HS V3. Good quality sequence
reads were trimmed to remove adapter sequences
and analyzed by using the sRNAbench 0.9 package
[65]. Reads were aligned to the human (reference
genome GRCh37) and EBV genome (NC_007605).
Initially, no mismatches were allowed between the
Illumina reads and the reference sequences. How-
ever, as we identified a single nucleotide change
(position 17, T changed to C) in the mature BART19-5p
miRNA sequence in the C666-1 EBV strain (as re-
ported before by Chen et al. [34]), read count num-
bers for this miRNA were adjusted to reflect the
correct miR-BART19-5p reads. We did not detect
additional polymorphisms in any of the analyzed cell
lines. Correlation coefficients were calculated using
Graphpad Prism.
MiRNA arm ratio calculations
miRNA arm ratios were calculated by dividing the num-
ber of reads of the most abundant arm by that of the
least abundant arm, to obtain numbers between 1 (1 : 1
ratio) and infinite (if one arm was undetectable). Data
from published studies were obtained from the NCBI
Sequence Read Archive (http://www.ncbi.nlm.nih.gov/
sra): Akata-LCL: SRR1003028 [66], BC-1: SRR343332
[67], rLCV-infected 211-98 rhesus macaque rLCL: run
SRR1003031 and run SRR1003028, rLCV-infected 309-
98 rhesus macaque rLCL: run SRR1003035 and run
SRR1003033 [66]. Deep sequencing reads were ana-
lyzed by using the sRNAbench 0.9 package, single
nucleotide mismatches to reference sequences were
allowed in the analysis.
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Additional files
Additional file 1: List of miRNA sequences and perfect target
sequences. List of miRNA sequences annotated in miRBase or (*) based
on deep sequencing data from Chen et al. 2010 (column 2). Perfect
target sequences (column 3) were cloned downstream of the mCherry
reporter gene to monitor miRNA expression. # The deep-sequencing
analysis in Fig. 3 identified a single nucleotide change (position 17, T
changed to C) in the mature miR-BART19-5p miRNA sequence in the
C666-1 strain. Therefore, the miR-BART19-5p miRNA sensor used in the
C666-1 cells to monitor miRNA activity does not fully match the
miR-BART19-5p sequence expressed in these cells (DOCX 20 kb)
Additional file 2: Good reproducibility between miRNA reporter assays.
Shown are the log-transformed relative reporter expression values of two
independent experiments (each representing three technical replicates)
in each of the four EBV+ cell lines. The data points are located close to
the diagonal dashed lines, indicating good reproducibility (PDF 121 kb)
Additional file 3: Comparison of functional EBV miRNA expression
between AKBM and other EBV+ cell lines. miRNA reporter expression
(data also shown in Fig. 1) was compared between AKBM and the three
other EBV+ cell lines. Every dot represents the relative reporter expression
of a specific miRNA as a percentage of the control reporter. The dashed
line indicates the diagonal (no difference in relative reporter expression
between both cell lines) (PDF 91 kb)
Additional file 4: Assessment of miRNA reporters in EBV− cells. Reporter
activity for miR-BART2-3p, miR-BART3-5p and controls was compared
between AKBM and the EBV− Burkitt’s lymphoma cell lines, 2A8 and AK31
(AKBM data also shown in Fig. 1). The miR-BART2-3p reporter is only
downregulated in AKBM but not in the other two cell lines, suggesting
that downregulation of the reporter is specific for EBV+ cells and thus
likely due to miR-BART2-3p expression. The miR-BART3-5p reporter was
downregulated in all three cell lines, suggesting the influence of a
common host cell factor such as a human miRNA on reporter
expression (PDF 101 kb)
Additional file 5: List of EBV miRNA sequence variants. The most highly
abundant sequence, the normalized sequence read counts (reads per
million genome-mapped reads), the percentage of canonical sequences
and percentage of 5’ terminus variants of each EBV miRNA in the five cell
lines are shown (XLSX 22 kb)
Additional file 6: AKBM cells are EBV positive. A) Schematic
representation of the EBV super-sensor. Five perfect EBV miRNA target
sites were cloned downstream of the mCherry reporter gene. The vector
allows for sensing of EBV presence by monitoring the combined func-
tional expression of 5 EBV miRNAs. B) EBV-positive AKBM cells and EBV
negative AK31 and 2A8 cells were either left untreated (cells alone),
were transduced with an mCherry-control vector (control sensor), or
were transduced with the EBV sensor from a). Cells were monitored
for mCherry reporter expression at 7 days post transduction by flow
cytometry (PDF 165 kb)
Additional file 7: Comparison of deep sequencing reads between
different cell lines. Deep sequencing reads were compared between the
four EBV+ cell lines and the EBV− cell line HK1-miR-BART. Every dot
represents a single miRNA arm. BHRF1 miRNAs, BART2-3p and BART2-5p
are not depicted in the HK1-miR-BART plots as these are not expressed in
these cells. Pearson correlations R square and p-values are presented.
Good correlations were observed between the read counts for BART
miRNAs in all combinations of cell lines (PDF 157 kb)
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